METHODS: An analytical cross-sectional study was conducted from March 2021 to February 2022, encompassing neonates admitted to the Department of Pediatrics with suspected neonatal septicemia, confirmed by positive blood cultures.
RESULTS: A total of 96 neonates were included, predominantly male (71.9%). Gram-negative bacteria constituted 61.6% of isolates, and the most common organism isolated was non-lactose fermenter group (38.4%) followed by coagulase-negative staphylococci (CoNS) (33.4%). Non-lactose fermenter group bacteria were prominent in EONS cases (44.6%), while CoNS predominated in LONS cases (51.6%). Birthplace, birth weight, and perinatal score were significantly associated with both EONS and LONS. Linezolid exhibited high efficacy against gram-positive bacteria, while ciprofloxacin and meropenem demonstrated effectiveness against various gram-negative pathogens. Methicillin-resistant Staphylococcus aureus (MRSA) strains exhibited resistance to all the antibiotics used in the study except for linezolid.
CONCLUSIONS: These findings underscore the importance of tailored empirical therapy guided by local epidemiological data to optimize clinical outcomes and mitigate antimicrobial resistance.
方法:从2021年3月至2022年2月进行了一项横断面分析研究,包括儿科收治的疑似新生儿败血症的新生儿,通过血培养阳性证实。
结果:共纳入96例新生儿,以男性为主(71.9%)。革兰氏阴性菌占分离株的61.6%,最常见的是非乳糖发酵罐组(38.4%),其次是凝固酶阴性葡萄球菌(CoNS)(33.4%)。非乳糖发酵罐组细菌在EONS病例中突出(44.6%),而CoNS在LONS病例中占主导地位(51.6%)。出生地,出生体重,围产期评分与EONS和LONS均显著相关。利奈唑胺对革兰氏阳性菌表现出很高的疗效,而环丙沙星和美罗培南对各种革兰阴性病原体均有效。耐甲氧西林金黄色葡萄球菌(MRSA)菌株对该研究中使用的所有抗生素均表现出耐药性,利奈唑胺除外。
结论:这些发现强调了以当地流行病学数据为指导的量身定制的经验性治疗对于优化临床结果和减轻抗菌药物耐药性的重要性。